JWA
HZNP

JFS Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

JFS Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-63
Closed -$7.29K – 2066
2023
Q3 		$7.29K Hold
63
– – ﹤0.01% 838
2023
Q2 		$6.48K Hold
63
– – ﹤0.01% 895
2023
Q1 		$6.88K Sell
63
-1
-2% -$111 ﹤0.01% 867
2022
Q4 		$7.28K Buy
64
+54
+540% +$4.49K ﹤0.01% 832
2022
Q3 		$1K Sell
10
-79
-89% -$5.52K ﹤0.01% 1711
2022
Q2 		$7K Sell
89
-37
-29% -$3.5K ﹤0.01% 913
2022
Q1 		$13K Sell
126
-65
-34% -$6.33K ﹤0.01% 727
2021
Q4 		$21K Sell
191
-360
-65% -$39.3K ﹤0.01% 560
2021
Q3 		$60K Buy
+551
New +$57.2K 0.01% 390

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JFS Wealth Advisors's HZNP Position: Q4 2023 in Review

JFS Wealth Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 63 shares — an estimated $7.29K sold.

JFS Wealth Advisors first reported a position in HZNP in Q3 2021 and held it in 9 quarters. The position peaked at $60K in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • JFS Wealth Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • JFS Wealth Advisors sold 63 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $7.29K.
  • JFS Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 9 quarters.
  • JFS Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $60K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on JFS Wealth Advisors's 13F filing for Q4 2023, filed 7 Feb 2024.